⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for refractory waldenstrom macroglobulinemia

Every month we try and update this database with for refractory waldenstrom macroglobulinemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom MacroglobulinemiaNCT01198067
Recurrent Walde...
Refractory Wald...
Pomalidomide
18 Years - M.D. Anderson Cancer Center
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell LymphomaNCT04635683
Recurrent B-Cel...
Recurrent Extra...
Recurrent Folli...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Recurrent Nodal...
Recurrent Splen...
Recurrent Walde...
Refractory B-Ce...
Refractory Extr...
Refractory Foll...
Refractory Grad...
Refractory Grad...
Refractory Grad...
Refractory Lymp...
Refractory Mant...
Refractory Marg...
Refractory Noda...
Refractory Sple...
Refractory Wald...
Lenalidomide
Ublituximab
Umbralisib
18 Years - Ohio State University Comprehensive Cancer Center
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin LymphomasNCT02332980
Recurrent B-Cel...
Recurrent Chron...
Recurrent Extra...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Lymph...
Recurrent Margi...
Recurrent Nodal...
Recurrent Small...
Recurrent Splen...
Recurrent Walde...
Refractory B-Ce...
Refractory Chro...
Refractory Extr...
Refractory Foll...
Refractory Lymp...
Refractory Noda...
Refractory Smal...
Refractory Sple...
Refractory Wald...
Richter Syndrom...
Waldenstrom Mac...
Ibrutinib
Idelalisib
Laboratory Biom...
Pembrolizumab
18 Years - Mayo Clinic
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell LymphomaNCT04635683
Recurrent B-Cel...
Recurrent Extra...
Recurrent Folli...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Recurrent Nodal...
Recurrent Splen...
Recurrent Walde...
Refractory B-Ce...
Refractory Extr...
Refractory Foll...
Refractory Grad...
Refractory Grad...
Refractory Grad...
Refractory Lymp...
Refractory Mant...
Refractory Marg...
Refractory Noda...
Refractory Sple...
Refractory Wald...
Lenalidomide
Ublituximab
Umbralisib
18 Years - Ohio State University Comprehensive Cancer Center
Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom MacroglobulinemiaNCT01198067
Recurrent Walde...
Refractory Wald...
Pomalidomide
18 Years - M.D. Anderson Cancer Center
Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom MacroglobulinemiaNCT03506373
Recurrent Walde...
Refractory Wald...
Waldenstrom Mac...
Ibrutinib
Ixazomib Citrat...
Laboratory Biom...
Pharmacodynamic...
Pharmacokinetic...
18 Years - Mayo Clinic
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin LymphomasNCT02332980
Recurrent B-Cel...
Recurrent Chron...
Recurrent Extra...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Lymph...
Recurrent Margi...
Recurrent Nodal...
Recurrent Small...
Recurrent Splen...
Recurrent Walde...
Refractory B-Ce...
Refractory Chro...
Refractory Extr...
Refractory Foll...
Refractory Lymp...
Refractory Noda...
Refractory Smal...
Refractory Sple...
Refractory Wald...
Richter Syndrom...
Waldenstrom Mac...
Ibrutinib
Idelalisib
Laboratory Biom...
Pembrolizumab
18 Years - Mayo Clinic
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: